U.S. Markets closed

Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why

Sarah Toy
Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why

Shares of Belgium-based biotech Galapagos NV soared 23% on Friday after the company, together with pharmaceutical giant Gilead Sciences Inc., announced Thursday evening that two Phase 3 trials of their investigational rheumatoid arthritis drug had achieved their primary endpoints.